Literature DB >> 18502264

Adiponectin and noncardiovascular death: a nested case-control study.

Masatoshi Matsumoto1, Shizukiyo Ishikawa, Eiji Kajii.   

Abstract

This study is to evaluate the associations between adiponectin level and noncardiovascular death and to test a hypothesis that adiponectin level reflects the degree of systemic wasting that precedes death. A nested case-control study was conducted involving 5243 subjects, drawn from 12490 subjects of the Jichi Medical School Cohort Study, whose blood samples had been drawn between 1992 and 1995. Over an average of 10.8 years of follow-up, 103 cases with noncardiovascular death and 565 controls without history/event/death of any cardiovascular disease were identified. Odds ratios (ORs) were estimated relative to the lowest quintile of adiponectin level. The risks for noncardiovascular death of the second lowest quintile and the highest quintile of adiponectin level were significantly higher than that of the lowest quintile when adjusted for age and sex (model 1) (OR, 2.38 [95% confidence interval (CI), 1.12-5.06] and 2.16 [1.01-4.80]). All the statistical significances disappeared when adjusted further for body mass index and C-reactive protein level (model 2). When excluding cases with cancer death, the odds for death in the highest 2 quintiles were significantly higher than those in the lowest quintile in model 1 (OR, 2.80 [95% CI, 1.04-7.59] and 3.74 [1.38-10.18]). The significant difference between the highest vs the lowest quintile remained significant in model 2 and even after adjusting further for smoking, diabetes, and total cholesterol level (model 3) (OR, 3.28 [95% CI, 1.02-10.51] and 3.98 [1.21-13.13]). Adiponectin levels had linear associations with the risks of noncardiovascular noncancer death in models 1, 2, and 3 (OR per 1 SD increase in log-adiponectin, 1.72 [95% CI, 1.23-2.40], 1.89 [1.23-2.91], and 2.01 [1.29-3.15]). Adiponectin is an independent indicator of noncardiovascular mortality that may relate with systemic wasting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18502264     DOI: 10.1016/j.metabol.2008.01.024

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  5 in total

1.  Is adiponectin a bystander or a mediator in heart failure? The tangled thread of a good-natured adipokine in aging and cardiovascular disease.

Authors:  Ken Shinmura
Journal:  Heart Fail Rev       Date:  2010-09       Impact factor: 4.214

2.  Association of Adiponectin With Cancer and All-Cause Mortality in a Japanese Community-Dwelling Elderly Cohort: A Case-Cohort Study.

Authors:  Reiji Kojima; Shigekazu Ukawa; Wenjing Zhao; Koji Suzuki; Hiroya Yamada; Kazuyo Tsushita; Takashi Kawamura; Satoe Okabayashi; Kenji Wakai; Hisashi Noma; Masahiko Ando; Akiko Tamakoshi
Journal:  J Epidemiol       Date:  2018-03-24       Impact factor: 3.211

3.  Alterations of HDL Particles in Children with End-stage Renal Disease.

Authors:  Aleksandra Stefanović; Danijela Ristovski-Kornic; Jelena Kotur-Stevuljević; Vesna Spasojević-Kalimanovska; Jelena Vekić; Milica Miljković; Dusan Paripović; Amira Peco-Antic; Zorana Jelić-Ivanović; Aleksandra Zeljković
Journal:  J Med Biochem       Date:  2017-10-28       Impact factor: 3.402

4.  Plasma adiponectin level and myocardial infarction: the JMS Cohort Study.

Authors:  Yu Hatano; Masatoshi Matsumoto; Shizukiyo Ishikawa; Eiji Kajii
Journal:  J Epidemiol       Date:  2009-03-06       Impact factor: 3.211

5.  Adiponectin gene polymorphisms and acute respiratory distress syndrome susceptibility and mortality.

Authors:  Amy M Ahasic; Yang Zhao; Li Su; Chau-Chyun Sheu; B Taylor Thompson; David C Christiani
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.